Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132612 · ClinicalTrials.gov registry record · Phase 2
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT01132612: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01132612 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 275 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01132612, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
Primary Outcome
Safety was assessed by frequency of adverse events including serious adverse events.
Interventions
- DRUG Placebo
- DRUG AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2010-05-11 |
| Est. Completion | 2016-10-18 |
| Phase | Phase 2 |
What the finished NCT01132612 record still lists
NCT01132612 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01132612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01132612 about?
NCT01132612 is a clinical study titled "AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis". The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT01132612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2010-05-11. Estimated completion is 2016-10-18.
What interventions are being tested in trial NCT01132612?
The interventions under investigation include: Placebo (DRUG), AIN457 (DRUG).
Who is sponsoring clinical trial NCT01132612?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01132612's enrollment target sits among peer trials
275 203rd of 2000 higher than 1,798 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI